{"id":61399,"date":"2025-06-10T10:03:26","date_gmt":"2025-06-10T08:03:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/"},"modified":"2025-06-10T10:03:26","modified_gmt":"2025-06-10T08:03:26","slug":"emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/","title":{"rendered":"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform"},"content":{"rendered":"<div>\n<p>\n<i>Built-in incubation, automated imaging, and AI-ready data generation deliver in vivo fidelity at scale<\/i><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/5\/Emulate_AVA.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/5\/Emulate_AVA.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/21\/Emulate_AVA.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/1451179\/5\/Emulate_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/1451179\/22\/Emulate_Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/1451179\/5\/Emulate_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/1451179\/21\/Emulate_Logo.jpg\"><\/a><\/p>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Femulatebio.com%2Fava&amp;esheet=54271420&amp;newsitemid=20250610950554&amp;lan=en-US&amp;anchor=AVA%26%238482%3B+Emulation+System&amp;index=1&amp;md5=64bee9a13a5e83aa1fdd2137c3051971\" rel=\"nofollow\" shape=\"rect\">AVA\u2122 Emulation System<\/a>, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of <i>in vivo<\/i>-level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory.<\/p>\n<p>\n\u201cAVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue\u2014something no other platform can match,\u201d said Jim Corbett, Chief Executive Officer at Emulate. \u201cBy combining Emulate\u2019s proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.\u201d<\/p>\n<p>\n<b>AVA Emulation System: Three Instruments in One<\/b><\/p>\n<p>\nAVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit.<\/p>\n<p>\nKey performance gains include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Expanded experimental power<\/i> \u2013 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli.<\/li>\n<li>\n<i>Lower operating costs<\/i> \u2013 AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology.<\/li>\n<li>\n<i>Time &amp; labor savings \u2013 <\/i>Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array\u2122 consumable that integrates 12 independent Organ-Chips into an<i> <\/i>SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers.<\/li>\n<li>\n<i>AI-ready datasets<\/i> \u2013 A typical 7-day experiment can generate &gt;30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions\u2014providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction.<\/li>\n<\/ul>\n<p>\n<b>A Timely Answer to Shifting Regulations<\/b><\/p>\n<p>\nWith the FDA targeting animal studies to become \u201cthe exception rather than the norm,\u201d the need for proven human models is urgent. Emulate\u2019s Liver-Chip S1\u2014the first and only Organ-Chip admitted to the FDA\u2019s ISTAND program\u2014has already outperformed animals, showing <b>87% sensitivity and 100% specificity<\/b> for drug-induced liver injury in a <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs43856-022-00209-1&amp;esheet=54271420&amp;newsitemid=20250610950554&amp;lan=en-US&amp;anchor=2022+Communications+Medicine+study&amp;index=2&amp;md5=d13d9cb1582e1c4077ecebfab14c3a20\" rel=\"nofollow\" shape=\"rect\">2022 <i>Communications Medicine<\/i> study<\/a>. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline.<\/p>\n<p>\n\u201cMoving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,\u201d noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. \u201cAVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.\u201d<\/p>\n<p>\n<b>Broad Impact Across Industries<\/b><\/p>\n<p>\nIn biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Femulatebio.com%2Forgan-chips-vs-nhps-cost-calculator%2F&amp;esheet=54271420&amp;newsitemid=20250610950554&amp;lan=en-US&amp;anchor=saved+millions+of+dollars+and+years+of+development+time&amp;index=3&amp;md5=f326f417cdf7d273c6d25c72a2fa56f8\" rel=\"nofollow\" shape=\"rect\">saved millions of dollars and years of development time<\/a> by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA\u2019s leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions\u2014bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike.<\/p>\n<p>\n<b>Availability<\/b><\/p>\n<p>\nGlobal orders are open immediately. For pricing or demonstrations, please <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Femulatebio.com%2Fcontact-sales%2F&amp;esheet=54271420&amp;newsitemid=20250610950554&amp;lan=en-US&amp;anchor=submit+a+request+here&amp;index=4&amp;md5=f3e0f5ec7d5b2c5f2bfd95e257c7a190\" rel=\"nofollow\" shape=\"rect\">submit a request here<\/a>.<\/p>\n<p>\n<b>About Emulate<\/b><\/p>\n<p>\nEmulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation <i>in vitro <\/i>models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research\u2014one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate\u2019s Organ-Chip platforms, consumables, and organ models help the world\u2019s leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.emulatebio.com&amp;esheet=54271420&amp;newsitemid=20250610950554&amp;lan=en-US&amp;anchor=www.emulatebio.com&amp;index=5&amp;md5=712dd698b34affb56163f9189c01dc17\" rel=\"nofollow\" shape=\"rect\">www.emulatebio.com<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFor media inquiries or additional information, please contact:<br \/>\n<br \/><b>Name<\/b>: Rebecca Bonfig<br \/>\n<br \/><b>Email<\/b>: <a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;P&#82;&#x43;&#111;&#x6d;m&#117;&#x6e;i&#x63;a&#116;&#x69;o&#x6e;&#x73;&#64;&#x65;m&#117;&#x6c;&#97;&#x74;e&#98;&#x69;&#111;&#x2e;c&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x50;&#x52;&#67;&#111;m&#x6d;&#x75;&#x6e;&#105;&#99;a&#x74;&#x69;&#x6f;&#110;&#115;&#64;&#x65;&#x6d;&#x75;&#108;&#97;t&#x65;&#x62;&#x69;&#111;&#46;c&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Built-in incubation, automated imaging, and AI-ready data generation deliver in vivo fidelity at scale BOSTON&#8211;(BUSINESS WIRE)&#8211;Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA\u2122 Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61399","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Built-in incubation, automated imaging, and AI-ready data generation deliver in vivo fidelity at scale BOSTON&#8211;(BUSINESS WIRE)&#8211;Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA\u2122 Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T08:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform\",\"datePublished\":\"2025-06-10T08:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/\"},\"wordCount\":757,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250610950554\\\/en\\\/2492782\\\/22\\\/Emulate_AVA.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/\",\"name\":\"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250610950554\\\/en\\\/2492782\\\/22\\\/Emulate_AVA.jpg\",\"datePublished\":\"2025-06-10T08:03:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250610950554\\\/en\\\/2492782\\\/22\\\/Emulate_AVA.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250610950554\\\/en\\\/2492782\\\/22\\\/Emulate_AVA.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/","og_locale":"en_US","og_type":"article","og_title":"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform - Pharma Trend","og_description":"Built-in incubation, automated imaging, and AI-ready data generation deliver in vivo fidelity at scale BOSTON&#8211;(BUSINESS WIRE)&#8211;Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA\u2122 Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-10T08:03:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform","datePublished":"2025-06-10T08:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/"},"wordCount":757,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/","url":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/","name":"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg","datePublished":"2025-06-10T08:03:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250610950554\/en\/2492782\/22\/Emulate_AVA.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/emulate-launches-ava-emulation-system-to-accelerate-drug-development-with-first-of-its-kind-high-throughput-organ-chip-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Emulate Launches AVA\u2122 Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61399"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61399\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}